Pharmas were resilient amid the October cliff in the market, with the fear-driven interest being well supported by the steady earnings, especially by the “Biggies’ in Q3. This was also…

Unilever has been known for its shareholder-friendly attitudes and timely delivery on its plans. Step by step, task after task, the company has been fulfilling its strategic plan until the…

The financial newspapers are making big titles about the private equity bubble. Bubble means that the average acquisition price is 10.2x EBITDA and gearing is 5.2x EBITDA. These are indeed…

The last few days’ storm has opened wide BUY opportunities. We contribute here a list concentrating on quality names, i.e. more of a growth profile and with stainless-steel balance sheets….

Although the cash flow statement is extensively used by the financial community in the analysis of non-financial companies, it is not at all when it comes to deposit banks as…

Unterschleißheim, Germany/Paris, France, 21 September 2018: Baader Helvea will be the exclusive distribution partner for the pan-European research product of AlphaValue, the leading provider of independent equity research based in…

So a bunch of early-moving hedge funds and a handful of traders rediscover the carbon rights market and turn European utilities into a casino-type wager on spot power prices? This, in a…

Alphavalue’s pharma coverage outperformed the Stoxx 600 last month, returning 1.35% vs a decline suffered by the Stoxx 600. Shire, Sanofi, Roche, Vifor and Faes Farma were the best performers…